Infinity Pharmaceuticals, Inc. INFI · Stock Open Infinity Pharmaceuticals, Inc. in new tab
Infinity Pharmaceuticals, Inc. Analysis (INFI)
Is Infinity Pharmaceuticals, Inc. a good investment? Infinity Pharmaceuticals, Inc. (INFI) is currently trading at 0.008000 USD.
Investor FAQ
Does Infinity Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Infinity Pharmaceuticals, Inc.?
Infinity Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Community Discussion